PEMF for
Pudendal Neuralgia.

August 2026 · 10 min read · Neuropathic Pain Protocol

What Is Pudendal Neuralgia?

Pudendal neuralgia (PN) is a chronic neuropathic pain condition caused by irritation, compression, or entrapment of the pudendal nerve — the primary sensory nerve of the perineum, originating from sacral roots S2, S3, and S4. It presents as burning, stabbing, or electric-shock pain in the vulva, penis, scrotum, perineum, or perianal region. A defining feature is positional sensitivity: pain worsens significantly with sitting and is relieved by standing or lying down.

PN affects an estimated 1% of the general population and up to 15% of patients presenting with chronic pelvic pain — making it one of the most prevalent yet most underdiagnosed neuropathic conditions in clinical practice. The average time from symptom onset to correct diagnosis is 3 to 5 years, during which patients cycle through urology, gynecology, colorectal, and orthopedic specialties without resolution.

Why the Pudendal Nerve Is Uniquely Vulnerable

The pudendal nerve traverses two anatomical danger zones: the Alcock's canal (pudendal canal) in the obturator fascia, and the lesser sciatic foramen between the sacrospinous and sacrotuberous ligaments. Entrapment at either site produces peripheral sensitization of A-δ and C fibers, followed by central sensitization of the sacral dorsal horn — the same cascade seen in interstitial cystitis, pelvic floor dysfunction, and CRPS.

Four contributing mechanisms make PN particularly resistant to standard analgesics:

1. Peripheral sensitization — chronic low-grade inflammation at entrapment sites upregulates TRPV1 and Nav1.8 channels, lowering pain thresholds.
2. Central sensitization — persistent afferent barrage reorganizes sacral dorsal horn circuitry, producing allodynia and hyperalgesia extending beyond the nerve territory.
3. Pelvic floor hypertonicity — guarding response creates a biomechanical compression cycle that perpetuates the entrapment.
4. Autonomic dysregulation — S2-S4 involvement disrupts parasympathetic outflow to bladder, bowel, and sexual function, creating comorbidities that compound the pain experience.

PEMF Mechanism in Pudendal Neuralgia

The non-invasive sacral neuromodulation model is the key conceptual bridge. Sacral neuromodulation (SNM) — delivered via implanted electrodes at S3 — is FDA-approved for chronic pelvic pain and overactive bladder via the same S2-S4 pathway that the pudendal nerve serves. PEMF applied in the sacral and perineal zones replicates this sacral gateway effect non-invasively:

• Adenosine-A2A receptor activation at sacral dorsal horn synapses suppresses substance P and CGRP release — the primary mediators of pudendal nerve central sensitization.
• Voltage-gated Na⁺ channel modulation (8-25 Hz) raises the action potential threshold of A-δ fibers in the pudendal territory, reducing spontaneous ectopic discharge.
• NF-κB suppression reduces pro-inflammatory cytokines (IL-1β, TNF-α) in perineural tissue, attenuating the inflammatory component of nerve entrapment.
• Pelvic floor muscle relaxation — Ca²⁺ channel modulation reduces smooth and striated muscle tone in the pelvic floor, breaking the mechanical compression cycle.
• Improved microcirculation in the Alcock's canal region reduces ischemia-driven nociception in compressed nerve segments.

Posterior tibial nerve stimulation (PTNS) RCTs — which operate through the same S2-S4 sacral reflex arc — have demonstrated significant pain reduction and bladder symptom improvement in pudendal neuralgia patients (AUA 2022, Grade B evidence), providing a validated mechanistic parallel for PEMF's sacral application.

Clinical Evidence Base

Clinical Protocol: Three-Phase Approach

Phase 1 — Anti-Inflammatory Foundation (Weeks 1–4, 3× weekly)

• Frequency: 8–25 Hz
• Coil placement: Dual — sacral (S2-S4 level) + perineal/suprapubic
• Session duration: 35–40 minutes
• Goal: Reduce perineural inflammation; lower spontaneous ectopic discharge; begin pelvic floor tone reduction

Phase 2 — Neuromodulation & Central Sensitization (Weeks 5–8, 2× weekly)

• Frequency: 25–50 Hz
• Coil placement: Sacral primary; add lumbar if lumbosacral contribution identified
• Session duration: 30–35 minutes
• Goal: Modulate sacral dorsal horn plasticity; suppress substance P and CGRP; improve bladder/bowel autonomic function

Phase 3 — Maintenance (Ongoing, 1–2× weekly)

• Frequency: 8–50 Hz (individualized)
• Goal: Sustain remission; prevent central sensitization recurrence
• Adjunct recommendation: Pelvic floor physiotherapy concurrent with PEMF series

Outcome Measures

• Nantes Criteria score — validated pudendal neuralgia diagnostic and tracking tool
• VAS pain score — baseline, week 4, week 8, week 12
• Pelvic Pain Impact Questionnaire (PPIQ)
• Bladder diary — voiding frequency and urgency (S2-S4 autonomic improvement)
• Sitting tolerance test — minutes comfortable sitting; objective functional marker

Comparison with Standard-of-Care Options

Philippines Market Context

Pudendal neuralgia is severely underdiagnosed in the Philippines. An estimated 1–2 million Filipinos live with chronic pelvic pain attributable to pudendal or sacral nerve pathology, yet fewer than 50 pain specialists in the country are trained in pudendal nerve diagnosis using the Nantes Criteria. The condition is routinely misattributed to recurrent urinary tract infection, vaginitis, hemorrhoids, or functional pelvic floor disorder — each generating cycles of repeated consultations without resolution.

The treatment gap is acute: SNM implants at ₱300,000–₱600,000 are accessible to fewer than 2% of the eligible population. Pudendal nerve blocks require a pain specialist or interventional radiologist — a referral chain unavailable in most provinces. Gabapentin is widely prescribed but poorly tolerated and produces only partial relief. This creates a substantial unmet-need population that a non-invasive, clinic-based PEMF sacral protocol directly addresses.

Contraindications

• Absolute: Active cardiac pacemaker or implantable cardioverter-defibrillator; active malignancy in the sacral or pelvic treatment field; epilepsy (active, uncontrolled)
• Relative (clearance required): Metallic pelvic implant or vaginal mesh — position coils to avoid direct overlay; pregnancy; intrauterine device — consult gynecologist before initiating sacral placement
• Clinical note: Exclude active pudendal nerve abscess or perineural cyst requiring surgical decompression prior to PEMF; these require urological or neurosurgical clearance first

What This Means for Clinic Investors

Pudendal neuralgia patients represent one of the highest-value PEMF treatment populations: they have failed multiple prior interventions, they are motivated by years of unresolved pain, and they complete full treatment courses. The niche is essentially uncontested in the Philippine market — no clinic-based non-invasive sacral neuromodulation protocol currently exists outside NCR, and even within NCR, specialist access is limited.

At 70+ Israeli clinics (population: 9M) — now expanding to the Philippines — the pudendal/sacral pain protocol is positioned as a high-complexity, premium service generating ₱1,500–₱2,500 per session, with average treatment courses of 16–24 sessions. A single PN patient generates ₱24,000–₱60,000 in clinic revenue while requiring no consumables beyond the PEMF device time.